Abstract: The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.

Abstract: A source driver and a method for color swapping are provided. The source driver includes: a processor configured to: obtain, from an application processor, a plurality of sub-pixel data, add a tag to each of the plurality of sub-pixel data to generate a plurality of new sub-pixel data, the tag indicating color information of the sub-pixel data, and perform color swapping on the plurality of new sub-pixel data; a multiplexer circuit communicatively coupled to the processor and configured to: obtain each of the plurality of color swapped new sub-pixel data in sequence, and select a corresponding gamma voltage according to the tag of the color swapped new sub-pixel data; and an analog amplifier circuit communicatively coupled to the multiplexer circuit and configured to provide a source driving signal to a corresponding sub-pixel in a pixel array according to the color swapped new sub-pixel data and the corresponding gamma voltage.

Abstract: This disclosure describes a biotechnological method for producing rebaudioside M (Reb M), using recombinantly produced glucosyltransferases, which can be carried out in a single reaction vessel using two glucosyltransferases and a uridine diphosphate glucose (UDPG) regenerating system. The method can be used to produce the commercially desirable Reb M from rubusoside, stevioside, or rebaudioside A (Reb A), which are all naturally more abundant steviol glycosides but with commercially less desirable properties.